Ranabir SinhaRoy
Regeneron (United States)(US)
Publications by Year
Research Areas
Diabetes Treatment and Management, Neuropeptides and Animal Physiology, Peptidase Inhibition and Analysis, Regulation of Appetite and Obesity, Receptor Mechanisms and Signaling
Most-Cited Works
- → Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice(2009)405 cited
- → Dipeptidyl Peptidase-4 Inhibitors Administered in Combination With Metformin Result in an Additive Increase in the Plasma Concentration of Active GLP-1(2010)176 cited
- → Omarigliptin (MK-3102): A Novel Long-Acting DPP-4 Inhibitor for Once-Weekly Treatment of Type 2 Diabetes(2014)167 cited
- → Optimization of co‐agonism at GLP‐1 and glucagon receptors to safely maximize weight reduction in DIO‐rodents(2012)134 cited
- → The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin(2012)106 cited
- → A comparative study of the binding properties, dipeptidyl peptidase‐4 (DPP‐4) inhibitory activity and glucose‐lowering efficacy of the DPP‐4 inhibitors alogliptin, linagliptin, saxagliptin, sitagliptin and vildagliptin in mice(2017)88 cited
- → DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives(2011)67 cited
- → Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin(2007)66 cited
- → A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates(2019)64 cited
- → Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice(2011)63 cited